Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
1.50 hr(s) | CME , NCPD , MOC , ABIM
Specialty: HER2-positive Breast Cancer
Therapeutic Area(s): Oncology
Release Date: June 14, 2021
Expiration Date: June 14, 2021
Location: Live Webcast
The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time.